Etiometry has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its new algorithm to track the clinical risk of inadequate oxygen delivery (IDO2) to critically ill babies in intensive care units (ICUs).

The firm’s Risk Analytics algorithms inform physicians and nurses in the ICU through T3 visualization and data aggregation software based on patient-specific data and models of human physiology.

The new algorithm will continuously evaluate patient-specific risk of inadequate oxygen delivery by computing an IDO2 Index, which reflects the likelihood that a critically ill baby in an ICU is experiencing the harmful physiologic state at any given time.

An increasing IDO2 is the sign of an increasing risk of inadequate oxygen delivery.

The IDO2 Index will be computed based on multiple physiologic measures and laboratory results collected by T3 visualization and data aggregation software.

Etiometry CEO Evan Butler said: “The Inadequate Oxygen Delivery (IDO2) Index Powered by Risk Analytics for Neonates is the first of many Etiometry algorithms that we are bringing to market.

“With the IDO2 algorithm, doctors and nurses can quickly assess the risk of inadequate oxygen delivery alongside traditional measures of the patient’s status in a manner that clearly visualizes the patient’s trajectory.”

Etiometry CTO Dr Dimitar Baronov said: “Our unique technology combines mechanistic models of human physiology and aerospace navigation techniques, which is Etiometry’s innovative approach for efficiently creating new algorithms by following a detailed and proprietary methodology.”

In September, the firm introduced platform, which offers hospital ICUs with actionable information via data consolidation, improved visualization, and predictive analytics.

The new Etiometry platform features a web-based architecture, which can be hosted in a hospital’s data center and protected by the hospital’s firewall.